Remove Drug Delivery Systems Remove Drugs Remove FDA Approval Remove Marketing
article thumbnail

Genentech’s New Ocular Implant Drug Delivery System for Macular Degeneration Could Be a Game Changer

XTalks

Genentech’s ocular implant drug delivery system for treatment of macular degeneration has received approval from the US Food and Drug Administration (FDA). Susvimo delivers ranibizumab via a port delivery system into a surgically placed implant in the eye, allowing for continuous delivery of the drug.

article thumbnail

IoT innovation: Leading companies in nanoparticles for drug delivery

Pharmaceutical Technology

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Key innovation: Leading companies in nanoparticles for drug delivery. Bristol-Myers Squibb is the leading patent filer in nanoparticles for drug delivery.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Five key drug discovery deals of summer 2023

Drug Discovery World

The new acquisition gives Biogen rights to Reata’s portfolio of products for neurological diseases, including the FDA-approved Skyclarys (omaveloxolone), the only approved treatment for Friedreich’s ataxia (FA) in the United States.

Drugs 52
article thumbnail

Top Emerging Therapies To Watch Out for in the Retinal Vein Occlusion Market

Delveinsight

Recent years started witnessing the emergence of novel treatment approaches that have been keeping the Retinal vein occlusion market in a hyped-up state. Looking at the potential of the pipeline therapies they hold once approved, pharmaceutical companies are charting out a seemingly exciting course in the market.

article thumbnail

What are the options available for the treatment of Retinal vein occlusion?

Delveinsight

However, for such a burdensome and highly prevalent sight-threatening eye disorder, the Retinal vein occlusion treatment market has no curative option to offer. Retinal vein occlusion drug market. Intraocular injections of steroids are another potential treatment for eyes that don’t respond to anti-VEGF drugs.

article thumbnail

To List or Not to List; That is the Question – The FTC Signals the Potential for Greater Scrutiny of Patent Information Submissions to FDA

FDA Law Blog

The six-page statement explains that “Brand drug manufacturers may be harming generic competition through the improper listing of patents in the. Of course, the statute says that only drug formulation, composition, or method of use patents are listable, but FDA has not defined the scope of the “drug” that must be covered by the patent.

Drugs 105
article thumbnail

Considerations for Neuroscience Trials with Intrathecal Delivery and Other Methods of Direct CNS Administration

XTalks

According to an analysis of the 2013 Medical Expenditure Panel Survey, one in six US adults reported taking a psychiatric drug at least once in 2013. Global sales of over-the-counter and prescription products related to central nervous system (CNS) disease added up to $86 billion in 2019.

Trials 83